J Med Cases
Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website http://www.journalmc.org

Case Report

Volume 8, Number 9, September 2017, pages 280-282


Piperacillin-Tazobactam-Induced Neutropenia: A Case Report

Diana Darwichea, Katia Iskandara, Rania Azara, Rabih Hallitb, Souheil Hallita, b, c, d, e

aFaculty of Pharmacy, Lebanese University, Beirut, Lebanon
bFaculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik, Kaslik, Lebanon
cFaculty of Pharmacy, Saint-Joseph University, Beirut, Lebanon
dResearch Department, Psychiatric Hospital of the Cross, PO Box 60096, Jal Eddib, Lebanon
eCorresponding Author: Souheil Hallit, Street 8, Building 560, 1st Floor, Biakout, Mount Lebanon, Lebanon

Manuscript submitted July 31, 2017, accepted August 22, 2017
Short title: Piperacillin/Tazobactam and Neutropenia
doi: https://doi.org/10.14740/jmc2889w

Abstract▴Top 

Piperacillin/tazobactam (TZP) is a beta-lactam antibiotic used for the treatment of many infections and is generally considered safe. Neutropenia is a rare but serious adverse effect of TZP. In this study, we present the case of piperacillin/tazobactam-induced neutropenia in an elderly patient, from which clinical data and blood samples were collected. Leucocytes and neutrophils counts were decreased on day 3 after initiating the treatment and worsened on day 5. We hypothesize that TZP might be able to cause neutropenia in a period shorter than 10 days. The relation between the duration of treatment with TZP and the onset of neutropenia requires additional studies.

Keywords: Piperacillin; Tazobactam; Neutropenia

Introduction▴Top 

Piperacillin/tazobactam (TZP) is a combination of a semi-synthetic ureidopenicillin and a beta-lactamase inhibitor, with an extended spectrum of action against beta-lactamase producing organisms and an increased activity against Pseudomonas aeruginosa when compared with other penicillins [1]. Its known adverse effects include hypersensitivity reactions, neurotoxicity, hepatotoxicity, electrolyte and acid-base disturbances, and bleeding disorders [1]. In addition, bone marrow suppression is a recognized adverse drug reaction of beta-lactam antibiotics, including neutropenia, thrombocytopenia and rarely hemolytic anemia [1]. A recent systematic review has supported the assumption that piperacillin can also have such adverse effects [2].

Neutropenia is defined as a decrease in the circulating neutrophils in the non-marginal pool to less than 1,500 cells/mm3 [3]. It is classified as mild, moderate or severe based on the absolute neutrophil count (ANC), with the latter measuring the number of neutrophil granulocytes present in the blood. Mild neutropenia is defined as an ANC of 1,000 - 1,500 cells/mm3, moderate neutropenia with an ANC of 500 - 1,000 cells/mm3, while severe neutropenia refers to an ANC lower than 500 cells/mm3 [4]. Most of the neutrophils are contained in the bone marrow, either as mitotically active or post-mitotic mature cells [5].

The reduced number of neutrophils makes patients extremely vulnerable to infection [6] and the risk of bacterial infection is related to both the severity and duration of the neutropenia.

There seems to be a relationship between the duration of TZP treatment and the onset of neutropenia. Most reviewed studies showed that neutropenia rarely develops before 10 days of treatment [7-9]. In one of the published case reports, a patient developed agranulocytosis on day 17 while receiving TZP treatment for an intracranial infection [10]. The mechanism by which TZP causes neutropenia is unclear but it is believed that piperacillin causes proliferation arrest of the myeloid cells [11]. Moreover, a published case report has detected immunologically mediated neutropenia in the presence of IgG antibodies against penicillins [12].

We report a case of neutropenia that occurred in a patient treated with TZP for pneumonia before 10 days of treatment. Monitoring for hematological parameters is crucial in a patient receiving piperacillin even for a short period.

Case Report▴Top 

A 91-year-old man with a history of diabetes and benign prostatic hypertrophy, treated with glimepiride and alfuzosin respectively, was admitted to the intensive care unit (ICU) at the Lebanese Canadian Hospital (Lebanon) in March 2017 with dyspnea. On admission, his temperature was 37 °C, with a blood pressure of 90/50 mm Hg, a pulse of 76 beats per minute and an oxygen saturation of 92% on room air. A chest X-ray showed a pleural effusion and a right lower lobe pneumonia. He was treated with TZP at a dose of 4.5 g IV every 8 h. The complete blood count at baseline (day 1) showed a microcytic hypochromic anemia (Hb = 10.4 g/L, Ht = 32 g/L, GR = 4.24, MCV = 76, MCH = 24), a white cell count (4,200 cells/mm3) (46% neutrophils). On day 2 and 3, the patient was hemodynamically stable and the dyspnea improved. On day 3, the patient developed a leucopenia with a white cell count of 2,900 cells/mm3 associated with neutropenia (neutrophils 46%). On day 5 of treatment, the neutropenia worsened (neutrophils 26%) and the white cell count was 3,000 cells/mm3 (Table 1). TZP was discontinued and the patient received levofloxacin. The white cell count came back to normal 3 days after stopping TZP (data not shown). The sputum culture was negative.

Table 1.
Click to view
Table 1. Laboratory Tests Results During Hospitalization
 
Discussion▴Top 

Piperacillin is an aminobenzyl penicillin derivative used for the treatment of infections caused by certain organisms (Pseudomonas aeruginosa, Klebsiella, etc.). Mild infections require a dose of 4 - 12 g/day; however, serious infections require a higher dose (12 - 24 g/day) [13]. In most studies, large cumulative doses are required for the onset of neutropenia, a side effect not commonly reported [1]. Neutropenia is an uncommon but serious adverse event of piperacillin. There have been several previous reports of neutropenia and bone marrow suppression following the use of piperacillin and TZP. A systematic review of studies on the relationship between piperacillin use and neutropenia suggests that the occurrence of neutropenia varies between 0.04% and 34% among individuals exposed to this drug [2]. Moreover, a retrospective cohort study in patients treated with piperacillin for osteomyelitis showed that 34% (14 of 41) of patients treated for more than 10 days developed neutropenia. It is of note that cumulative doses of piperacillin administered to neutropenic patients were higher than those administered to non-neutropenic ones [14].

In six previous reports of patients receiving piperacillin to treat osteomyelitis, pneumonia, cystic fibrosis and abscess, neutropenia has been reported 15 days after the start of therapy [7, 9, 12]. In four other published case reports of patients between 19 and 50 years, receiving TZP (dose = 4.5 g IV every 8 h) to treat pancreatic infections, pneumonia, osteomyelitis, neutropenia has been reported 16 - 25 days after initiation of treatment [9, 15, 16]. In one of these cases, the patient received metronidazole and amikacin as well. However, metronidazole was unlikely to be the cause because it had been administered 12 h prior to the appearance of neutropenia and amikacin had never been implicated as a cause of neutropenia [15]. Bone marrow examination in another case detected a maturation arrest of granulocytic cells [9]. After suspecting a TZP-induced bone marrow suppression due to TZP, the medication was discontinued immediately in all cases, with the neutrophil counts recovering completely 4 - 6 days after stopping the drug [9, 15, 16].

A retrospective analysis in 38 children with cystic fibrosis (age = 14 years) receiving TZP courses had detected six cases of fever, malaise, and headache during treatment without signs of acute infection. Out of these 38 cases, three children developed neutropenia between day 11 and day 15 of treatment. These children had received a higher cumulative dose of TZP than in the unaffected group. After discontinuation of TZP, blood cell counts were normalized [17].

Moreover, FDA Adverse Event Reporting System Database (AERS Database) detected 366 cases of hematological disorders (50% neutropenia and 27% leucopenia) following piperacillin administration, with neutropenia occurring on days 5 - 15 in 62 of these cases.

Bone marrow toxicity, mainly neutropenia, has been described as an uncommon secondary effect of TZP, and is usually related to large cumulative dose in many published cases [9, 15-17]. In our 91-year-old patient, neutropenia occurred without evidence of cumulative dose administered. Thus, we hypothesize that the neutropenia can be related to the medication itself and not to the cumulative dose. Further research are needed to evaluate this correlation.

Conclusion

Bone marrow suppression, especially neutropenia, is a serious adverse effect of TZP, which should be kept in mind while treating patients with this drug. Neutropenia occurred 3 days after the start of piperacillin treatment, despite being reported after 10 days of treatment in previous papers. Therefore, the association between the duration of treatment with TZP and the onset of neutropenia requires additional studies.

Conflicts of Interest

The authors have nothing to disclose.

Funding

The authors received no funding from an external source.


References▴Top 
  1. Kucers A, Crowe S, Grayson M, Hoy J. The use of antibiotics: a clinical review of antibacterial. Antifungal and Antiviral Drugs. 1997:1214.
  2. Scheetz MH, McKoy JM, Parada JP, Djulbegovic B, Raisch DW, Yarnold PR, Zagory J, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007;30(4):295-306.
    doi pubmed
  3. Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M. Descriptive epidemiology of agranulocytosis. Arch Intern Med. 1992;152(7):1475-1480.
    doi pubmed
  4. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med. 1999;133(1):15-22.
    doi pubmed
  5. Smith C. Production, distribution, and fate of neutrophils. Williams hematology. 2006:9.
  6. Palmblad J, Nilsson CC, Hoglund P, Papadaki HA. How we diagnose and treat neutropenia in adults. Expert Rev Hematol. 2016;9(5):479-487.
    doi pubmed
  7. Gerber L, Wing EJ. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin Infect Dis. 1995;21(4):1047-1048.
    doi pubmed
  8. Rye PJ, Roberts G, Staugas RE, Martin AJ. Coagulopathy with piperacillin administration in cystic fibrosis: two case reports. J Paediatr Child Health. 1994;30(3):278-279.
    doi pubmed
  9. Khan F. Severe neutropenia secondary to piperacillin/tazobactam therapy. Indian Journal of Pharmacology. 2005;37:192.
    doi
  10. He ZF, Wu XA, Wang YP. Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam. Scand J Infect Dis. 2013;45(11):885-887.
    doi pubmed
  11. Neftel KA, Hauser SP, Muller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985;152(1):90-98.
    doi
  12. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol. 1996;95(4):611-612.
    doi pubmed
  13. Winston DJ, Murphy W, Young LS, Hewitt WL. Piperacillin therapy for serious bacterial infections. Am J Med. 1980;69(2):255-261.
    doi
  14. Peralta FG, Sanchez MB, Roiz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis. 2003;37(11):1568-1572.
    doi pubmed
  15. Kumar A, Choudhuri G, Aggarwal R. Piperacillin induced bone marrow suppression: a case report. BMC Clin Pharmacol. 2003;3:2.
    doi pubmed
  16. Suntur BM, Kuscu F, Hava K, Dalkiran PA. [Piperasilin/tazobaktama bagli notropeni gelisen bir olgu sunumu]. Ege Tip Dergisi. 2015;54.
  17. Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment - a retrospective analysis in 38 children with cystic fibrosis. Infection. 1999;27(6):355-356.
    doi pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Medical Cases is published by Elmer Press Inc.

 

Browse  Journals  

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.